DDInter675 DDInter448
Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule. Other esmolol formulations are still available for use.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Esmolol {u} (Compound) downregulates {v} (Gene) STX4
STX4 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Esmolol {u} (Compound) downregulates {v} (Gene) GTPBP8
GTPBP8 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Esmolol {u} (Compound) causes {v} (Side Effect) Respiratory failure
Respiratory failure {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Esmolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Esmolol {u} (Compound) resembles {v} (Compound) Sotalol
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Esmolol {u} (Compound) downregulates {v} (Gene) STX4
STX4 {u} (Gene) is regulated by {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Crizotinib
Esmolol {u} (Compound) causes {v} (Side Effect) Respiratory failure
Respiratory failure {u} (Side Effect) is caused by {v} (Compound) Gefitinib
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Esmolol {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Crizotinib
Esmolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} (Compound) downregulates {v} (Gene) PTK2B
PTK2B {u} (Gene) is bound by {v} (Compound) Crizotinib
Esmolol (Compound) downregulates STX4 (Gene) and STX4 (Gene) is upregulated by Crizotinib (Compound)
Esmolol (Compound) downregulates GTPBP8 (Gene) and GTPBP8 (Gene) is downregulated by Crizotinib (Compound)
Esmolol (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Crizotinib (Compound)
Esmolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Esmolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Esmolol (Compound) resembles Sotalol (Compound) and Sotalol may lead to a major life threatening interaction when taken with Crizotinib
Esmolol (Compound) downregulates STX4 (Gene) and STX4 (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Crizotinib (Compound)
Esmolol (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Gefitinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Esmolol (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Esmolol (Compound) resembles Pindolol (Compound) and Pindolol (Compound) downregulates PTK2B (Gene) and PTK2B (Gene) is bound by Crizotinib (Compound)